Status and research progress of oral anticoagulant therapy for venous thromboembolism

Abstract

Venous thromboembolism (VTE) is a common clinical vascular diseases. It is also one of the common complications during the perioperative period. VTE includes deep venous thrombosis (DVT) and pulmonary embolism. DVT could develop to pulmonary embolism unless received effective treatment in time. VTE is a common clinical reason that causing death of patients with VTE. Therefore, much attention should be paid to correct and standardize treatments of VTE. At present, the dominating clinical treatment of VTE is anticoagulant therapy. Direct oral anticoagulants, especially novel oral anticoagulants, such as rivaroxaban and dabigatran etexilate etc., play an important role in treatment of VTE. In this article, recent research progresses of oral anticoagulant therapy for VTE are summarized in terms of drug classification, dosage, treatment stratagies, anticoagulant principle and prognosis. Key words: Anticoagulants; Venous thrombosis; Venous thromboembolism; Thromboembolism; Pulmonary embolism; Blood coagulation factor inhibitors; Warfarin